Who patient advocates are and where they already have a say
Patient advocates bring varied personal and professional experience to research, regulation and healthcare decisions. They may speak from illness, caregiving or specialist knowledge, but no individual can represent every experience within a patient community.
Backgrounds and representation gaps
Patient advocates are a diverse group with no fixed limit on who can take the role; passion is a common thread. Scientific or medical understanding should not be presumed low: one prominent European advocate has both an MD and a PhD. A single advocate cannot fully represent a community, as when survivors speak for people with a low-survival disease.
Severely ill patients may be unable to advocate, while relatives are occupied with care and later grief; bereaved families may lack the inclination, capacity or knowledge to advocate for others. An oesophageal-cancer family advocate found that organisations' emphasis on survival and hope left people with profound needs insufficiently represented because most people did not want to discuss death.
Building advocacy expertise
One bereaved family advocate developed her skills through freelance medical writing, professional-association membership and a programme of study. Her preparation included three foundation medical-device regulatory-writing workshops to assess benefit and risk in oesophageal-cancer devices, an end-of-life doula foundation course to support terminally ill people and families, and a year of study to become a EUPATI fellow, gain standing and collaborate with peers. Her subsequent work included a Cancer Grand Challenges team, a patient-centred-care conference poster being developed into a review article, and preparation of an online palliative support group for oesophageal-cancer patients.
Roles in research and assessment
Patient advisory boards provide pharmaceutical companies with insight, and advocates sit on grant-review panels. Ethics committees usually include someone representing the local patient community, who may have the disease, be a caregiver or understand the patient perspective.
By July 2024 established advocacy roles included helping recruit trial participants, particularly in rare diseases, joining study steering committees, disseminating safety updates and results, influencing marketing-authorisation decisions and contributing to UK health technology assessment. In 2021 NICE's Public Involvement Programme supported patient and public participation across its programmes. Patients' contributions identified issues that mattered to them and questions for clinicians, adding value to guidance development and shared decision-making.
Advocates also addressed medical writers directly: at EMWA's 2017 pharmacovigilance expert seminar, they explained what patients wanted from documents and why understanding them mattered. An ALS advocacy group rated clinical trials publicly, acting as a consumer organisation that made patient priorities visible to sponsors.
Strength of the patient voice
A NICE public-involvement account played in July 2024 described greater acceptance of patient participation than fifteen years earlier, when some dismissed it as political correctness. NICE had at least two patients at any one committee meeting, but its head of public involvement favoured more patient members to strengthen their voice and represent a wider range of views and experience.